Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03982199




Registration number
NCT03982199
Ethics application status
Date submitted
10/06/2019
Date registered
11/06/2019
Date last updated
16/05/2024

Titles & IDs
Public title
A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
Scientific title
A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older
Secondary ID [1] 0 0
VAC18193RSV2001
Secondary ID [2] 0 0
CR108634
Universal Trial Number (UTN)
Trial acronym
CYPRESS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Respiratory Syncytial Viruses 0 0
Respiratory Tract Diseases 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - RSV Vaccine
Other interventions - Placebo

Experimental: Group 1: RSV Vaccine - Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, and 1C to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, and 3 years respectively after the first vaccination.

Placebo Comparator: Group 2: Placebo - Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, and 2C, and will first receive Ad26.RSV.preF based vaccine at years 1, 2, and 3. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.


Other interventions: RSV Vaccine
Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.

Other interventions: Placebo
Participants will receive a single IM injection of placebo control on Day 1.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD)
Timepoint [1] 0 0
From screening up to 2 years 9 months
Secondary outcome [1] 0 0
Number of Participants With Any RT-PCR-confirmed RSV Disease
Timepoint [1] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [2] 0 0
RSV A2 Strain Neutralization Antibody Titers
Timepoint [2] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [3] 0 0
Pre-Fusion Immunoglobulin G (IgG) Serum Antibody Response as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)
Timepoint [3] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [4] 0 0
Post-Fusion IgG Serum Antibody Response as Assessed by ELISA
Timepoint [4] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [5] 0 0
Interferon-gamma (IFN-gamma) T-Cells Responses Analyzed by Enzyme-linked Immunospot Assay (ELISpot)
Timepoint [5] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [6] 0 0
Number of Participants With Solicited Local Adverse Events (AEs) up to 7 Days After First Vaccination
Timepoint [6] 0 0
Up to Day 8 (7 days after first vaccination on Day 1)
Secondary outcome [7] 0 0
Number of Participants With Solicited Systemic AEs up to 7 Days After First Vaccination
Timepoint [7] 0 0
Up to Day 8 (7 days after first vaccination on Day 1)
Secondary outcome [8] 0 0
Number of Participants With Unsolicited AEs up to 28 Days After First Vaccination
Timepoint [8] 0 0
Up to Day 29 (28 days after first vaccination on Day 1)
Secondary outcome [9] 0 0
Number of Participants With Solicited Local AEs 7 Days After Re-vaccination at 1, 2 and 3 Years
Timepoint [9] 0 0
7 days after re-vaccination at 1, 2 and 3 years
Secondary outcome [10] 0 0
Number of Participants With Solicited Systemic AEs 7 Days After Re-vaccination at 1, 2 and 3 Years
Timepoint [10] 0 0
7 days after re-vaccination at 1, 2 and 3 years
Secondary outcome [11] 0 0
Number of Participants With Unsolicited AEs 28 Days After Re-vaccination at 1, 2 and 3 Years
Timepoint [11] 0 0
28 days after re-vaccination at 1, 2 and 3 years
Secondary outcome [12] 0 0
Number of Participants With Serious Adverse Events (SAEs) During the RSV Season
Timepoint [12] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [13] 0 0
Number of Participants With Adverse Events of Special Interests (AESI) During the RSV Season
Timepoint [13] 0 0
From screening up to end of the study (up to 3 years 9 months)
Secondary outcome [14] 0 0
Number of Participants With SAE During ARI Follow-up Period
Timepoint [14] 0 0
Up to 2 years 9 months

Eligibility
Key inclusion criteria
* Participant must have a body mass index (BMI) less than (<)40 kilogram per meter square (kg/m^2)
* Before randomization, a woman must be: postmenopausal (postmenopausal state is defined as no menses for 12 months without an alternative medical cause); and not intending to conceive by any methods
* Participant must be either in good or stable health. Participants may have mild to moderate underlying illnesses such as chronic cardiac diseases and chronic lung disease (asthma and chronic obstructive pulmonary disease [COPD]), congestive heart failure (CHF), hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms and signs are stable and medically controlled in the judgment of the investigator. Participants will be included on the basis of physical examination, medical history, and vital signs performed between informed consent form (ICF) signature and vaccination on Day 1
* From the time of vaccination through 3 months after vaccination, participant agrees not to donate blood
* Participant must be able to read, understand, and complete questionnaires in the eDiary (or a paper safety diary, if designated by the sponsor)
* Participant must be willing to provide verifiable identification, have means to be contacted and to contact the investigator during the study
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Participant has an acute illness (including acute respiratory illnesses) or body temperature greater than or equal to (>=)38.0 degree Celsius (ºC) within 24 hours prior to administration of study vaccine. In such a situation, enrollment at a later date is permitted
* Participant has a severe or potentially life-threatening chronic disorder such as severe chronic cardiac diseases and severe chronic lung disease (asthma and COPD), advanced CHF, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example: compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
* Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence)
* Per medical history, participant has chronic active hepatitis B or hepatitis C infection
* Per medical history, participant has human immunodeficiency virus (HIV) type 1 or type 2 infection
* Participant has a known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine components (including any of the constituents of the study vaccine)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/05/2023
Sample size
Target
Accrual to date
Final
5815
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Minnesota
Country [13] 0 0
United States of America
State/province [13] 0 0
Missouri
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Rhode Island
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Vaccines & Prevention B.V.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Vaccines & Prevention B.V. Clinical Trial
Address 0 0
Janssen Vaccines & Prevention B.V.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03982199